IMRX has 36-month beta value of 0.37. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy”, 2 as “overweight”, 1 as “hold”, and 0 as “sell”.
The public float for IMRX is 25.82M, and currently, short sellers hold a 3.46% ratio of that float. The average trading volume of IMRX on July 08, 2025 was 1.09M shares.
IMRX stock’s latest price update
Immuneering Corp (NASDAQ: IMRX) has experienced a rise in its stock price by 17.39% compared to its previous closing price of $3.45. However, the company has seen a gain of 14.73% in its stock price over the last five trading days. globenewswire.com reported 2025-06-17 that – 94% OS and 72% PFS observed at 6 months for atebimetinib (IMM-1-104) in combination with modified Gemcitabine/nab-paclitaxel (mGnP), N=34; median OS and PFS not yet reached – – Striking tumor reductions with 39% overall response rate and 81% disease control rate observed as of the data cutoff, including many patients with deepening, durable regressions and multiple examples of individual lesions rendered undetectable – – Markedly favorable tolerability profile observed, demonstrating potential best-in-class profile – – Pivotal trial of atebimetinib in combination with mGnP in first-line pancreatic cancer patients planned for 2026 – – Company to host conference call at 8:00 a.m. ET today – CAMBRIDGE, Mass.
IMRX’s Market Performance
IMRX’s stock has risen by 14.73% in the past week, with a monthly rise of 106.63% and a quarterly rise of 168.21%. The volatility ratio for the week is 13.01% while the volatility levels for the last 30 days are 16.93% for Immuneering Corp The simple moving average for the past 20 days is 47.30% for IMRX’s stock, with a 107.88% simple moving average for the past 200 days.
Analysts’ Opinion of IMRX
Needham, on the other hand, stated in their research note that they expect to see IMRX reach a price target of $15, previously predicting the price at $20. The rating they have provided for IMRX stocks is “Buy” according to the report published on March 15th, 2024.
Jefferies gave a rating of “Hold” to IMRX, setting the target price at $3 in the report published on March 15th of the previous year.
IMRX Trading at 104.32% from the 50-Day Moving Average
After a stumble in the market that brought IMRX to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 4.56% of gains for the given period.
Volatility was left at 16.93%, however, over the last 30 days, the volatility rate increased by 13.01%, as shares surge +97.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +187.23% upper at present.
During the last 5 trading sessions, IMRX rose by +14.73%, which changed the moving average for the period of 200-days by +41.11% in comparison to the 20-day moving average, which settled at $2.75. In addition, Immuneering Corp saw 271.56% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMRX starting from HAUSMAN DIANA, who purchase 3,000 shares at the price of $3.62 back on Jul 02 ’25. After this action, HAUSMAN DIANA now owns 3,000 shares of Immuneering Corp, valued at $10,874 using the latest closing price.
HAUSMAN DIANA, the Director of Immuneering Corp, purchase 2,500 shares at $3.60 during a trade that took place back on Jul 02 ’25, which means that HAUSMAN DIANA is holding 2,500 shares at $8,989 based on the most recent closing price.
Stock Fundamentals for IMRX
The total capital return value is set at -1.41%. Equity return is now at value -102.48%, with -89.10% for asset returns.
Based on Immuneering Corp (IMRX), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -13.13.
Currently, EBITDA for the company is -63.69 million with net debt to EBITDA at 0.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.48.
Conclusion
To put it simply, Immuneering Corp (IMRX) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
